文献速递消化系统肿瘤

纤维板层型肝癌:挑战与应对

Fibrolamellar carcinoma: Challenging the challenge.
PubMed 文献 · Eur J Cancer · 2020-08-05

纤维板层型肝癌(FLC)是一种罕见且认识不足的恶性肿瘤,多见于年轻患者。由于前瞻性临床试验困难,文献多为个案报道。目前最有前景的系统治疗是5-FU持续输注联合每3周一次IFN-α-2B,基于II期试验结果,本文结合自身真实世界经验证实其活性和获益,并讨论IFN-α-2B可及性受限等挑战。

要点

  • FLC罕见,前瞻性试验困难,证据多来自个案报道。
  • 5-FU输注联合3周一次IFN-α-2B是迄今最有前景的系统治疗。
  • IFN-α-2B可及性日益受限,可能影响未来获得有效治疗。

核心结论

  • 5-FU输注联合每3周一次IFN-α-2B在真实世界中对FLC显示活性和治疗获益。
  • IFN-α-2B可及性日益受限,可能危及未来FLC患者获得有效治疗。

研究设计与样本

  • 本文为综述,结合自身真实世界经验与文献回顾,讨论FLC治疗挑战。
  • 文献中化疗药物包括顺铂、表柔比星、5-FU和重组干扰素α-2B,多为个案报道。

主要发现

  • 5-FU输注联合每3周一次IFN-α-2B的II期临床试验结果支持其作为最有前景的系统治疗。
  • 本文真实世界经验证实该方案的活性和治疗获益。

关键数值与推荐

  • 5-FU输注联合每3周一次IFN-α-2B为基于II期试验的最有前景系统治疗方案。

临床怎么用

  • 对晚期FLC可考虑5-FU输注联合每3周一次IFN-α-2B方案。
  • 需关注IFN-α-2B可及性,提前规划治疗获取途径。

局限性

  • FLC罕见,前瞻性临床试验困难,可用数据稀少。
  • 文献证据多为个案报道,缺乏大规模研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fibrolamellar carcinoma (FLC) is a rare and poorly understood malignancy, which seems to be more prevalent in young patients compared with conventional hepatocellular carcinoma (HCC). Performing prospective clinical trials recruiting patients diagnosed with FLC has proven challenging with scarce data available guiding clinical management. The use of a number of chemotherapy compounds in these patients, including cisplatin, epirubicin, 5-fluorouracil (5-FU) and recombinant interferon α-2B (IFN-α-2B), has been reported in the literature, mainly in the form of case reports. The most promising systemic therapy tested so far is the combination of 5-FU infusion and 3-weekly IFN-α-2B, based on results from a phase II clinical trial. This article provides an overview of our own experience with this treatment schedule for patients with FLC, confirming its activity and treatment-derived benefit in the real world. Current challenges being faced by healthcare professionals treating patients with advanced FLC are discussed, especially the increasingly limited access to IFN-α-2B, which could compromise the access to an active therapy in the coming future, and the difficulties in the development of new treatment options for advanced FLC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lamarca A, Frizziero M, Fulton A, et al. Fibrolamellar carcinoma: Challenging the challenge. Eur J Cancer. 2020. PMID: 32768872. doi:10.1016/j.ejca.2020.06.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。